Dr. Jan Holmgren Receives 2017 Albert B. Sabin Gold Medal Award

WASHINGTON, D.C. – April 25, 2017 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Jan Holmgren with the 2017 Albert B. Sabin Gold Medal Award. Dr. Holmgren will be recognized for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.

Sabin Vaccine Institute Names Deputy Assistant Secretary for Health as New President of Global Immunization

WASHINGTON, D.C., February 13, 2017 – Sabin Vaccine Institute (Sabin), a non-profit dedicated to making life-improving vaccines more accessible, enabling innovation and expanding immunization across the globe, today announced the appointment of Dr. Bruce Gellin as President, Global Immunization. Dr. Gellin, a 15-year U.S. Department of Health and Human Services (HHS) veteran, has served as Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office since 2002. Among his roles, Dr. Gellin led discussions on behalf of the United States at high-level global and domestic policy advisory groups and was responsible for developing the National Vaccine Plan, our country's blueprint for all aspects of vaccines and immunization.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

By the Dengue Vaccine Initiative

For many people throughout the world, the bite of a mosquito is nothing more than a common annoyance. But for individuals living in dengue endemic countries such an annoyance can quickly turn into a life threatening condition.
Earlier this week 13 pharmaceutical companies*, together with several government and nongovernmental organizations**, pledged to find solutions to eliminate or control 10 neglected tropical diseases (NTDs) by the year 2020. At an event in London, pharmaceutical companies committed to invest in research and development (R&D) to find new treatments for NTDs along with increasing donations of existing drugs.

Last week leaders in global health and tropical medicine convened in Philadelphia to talk about the latest scientific advances in their field as well as the current status of efforts to control tropica